{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:21:02Z","timestamp":1790259662803,"version":"4.1.0"},"reference-count":241,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jtos.2015.10.002","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T03:45:22Z","timestamp":1446781522000},"page":"2-19","source":"Crossref","is-referenced-by-count":135,"title":["Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis \u2013 A Comprehensive Review and Guide to Therapy. I. Systemic Disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Sahar","family":"Kohanim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiria","family":"Palioura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajirah N.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen K.","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Amescua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayan","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preston H.","family":"Blomquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Dart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowu","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.P.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren G.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah S.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iason S.","family":"Mantagos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodhbir S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Pflugfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virender S.","family":"Sangwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly C.","family":"Sippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Sotozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald T.H.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scheffer C.G.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Ueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chodosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2015.10.002_bib1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Borchers","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtos.2015.10.002_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/BCR.0b013e3181848bb1","article-title":"Toxic epidermal necrolysis clinical guidelines","volume":"29","author":"Endorf","year":"2008","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.jtos.2015.10.002_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.jtos.2015.10.002_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(97)11369-1","article-title":"Toxic epidermal necrolysis","volume":"351","author":"Becker","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jtos.2015.10.002_bib6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/archderm.1990.01670320127028","article-title":"Incidence of toxic epidermal necrolysis in Italy","volume":"126","author":"Naldi","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archderm.1991.01680050083008","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany","volume":"127","author":"Schopf","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archderm.1991.01680050075007","article-title":"A\u00a0population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures","volume":"127","author":"Strom","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","article-title":"Clinical research for rare disease: opportunities, challenges, and solutions","volume":"96","author":"Griggs","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jtos.2015.10.002_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/pds.1105","article-title":"Cutaneous adverse drug reactions: a 9-year study from a South Indian Hospital","volume":"14","author":"Sushma","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtos.2015.10.002_bib11","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D397D8T291","article-title":"Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain","year":"2002","journal-title":"Dermatology Online J"},{"key":"10.1016\/j.jtos.2015.10.002_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-4362.1993.tb02814.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand","volume":"32","author":"Leenutaphong","year":"1993","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.110749","article-title":"A\u00a0systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population","volume":"79","author":"Patel","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jtos.2015.10.002_bib16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1542\/peds.2010-3322","article-title":"Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"128","author":"Finkelstein","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtos.2015.10.002_bib17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00007611-198005000-00015","article-title":"Etiologic factors of the Stevens-Johnson syndrome","volume":"73","author":"Yetiv","year":"1980","journal-title":"South Med J"},{"key":"10.1016\/j.jtos.2015.10.002_bib18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1590\/S0004-27492009000300017","volume":"72","author":"Franca","year":"2009","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jtos.2015.10.002_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006454-200102000-00022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system","volume":"20","author":"Ball","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jtos.2015.10.002_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3349\/ymj.2012.53.1.228","article-title":"Toxic epidermal necrolysis with ocular involvement following vaccination for hemorrhagic fever with renal syndrome","volume":"53","author":"Hwang","year":"2012","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jtos.2015.10.002_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1468-3083.1999.tb00846.x","article-title":"Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination","volume":"13","author":"Dobrosavljevic","year":"1999","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jtos.2015.10.002_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archderm.1974.01630070067017","article-title":"Fumigant-induced toxic epidermal necrolysis","volume":"110","author":"Radimer","year":"1974","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib23","first-page":"135","article-title":"Work-related toxic epidermal necrolysis?","volume":"34","author":"House","year":"1992","journal-title":"J\u00a0Occup Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jhm.639","article-title":"Toxic epidermal necrolysis (TEN) associated with herbal medication use in a patient with systemic lupus erythematosus","volume":"5","author":"Hemmige","year":"2010","journal-title":"J\u00a0Hosp Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib25","first-page":"3631","volume":"157","author":"Fogh","year":"1995","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.jtos.2015.10.002_bib26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1346-8138.1998.tb02477.x","article-title":"Stevens-Johnson syndrome caused by a health drink (Eberu) containing ophiopogonis tuber","volume":"25","author":"Mochitomi","year":"1998","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib27","first-page":"714","article-title":"Serious cutaneous adverse reactions to traditional Chinese medicines","volume":"46","author":"Lim","year":"2005","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jtos.2015.10.002_bib28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/0128071-200809060-00008","article-title":"Mycoplasma pneumoniae-associated mucositis with minimal skin manifestations","volume":"9","author":"Figueira-Coelho","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02113442","article-title":"Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection","volume":"14","author":"Fournier","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jtos.2015.10.002_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2332\/allergolint.11-OA-0309","article-title":"Statistical analysis of Stevens-Johnson syndrome caused by Mycoplasma pneumonia infection in Japan","volume":"60","author":"Kunimi","year":"2011","journal-title":"Allergol Int"},{"key":"10.1016\/j.jtos.2015.10.002_bib31","first-page":"740","article-title":"Mycoplasma pneumoniae and mucositis\u2013part of the Stevens-Johnson syndrome spectrum","volume":"10","author":"Meyer Sauteur","year":"2012","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jtos.2015.10.002_bib32","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/pde.12482","article-title":"Mycoplasma pneumoniae-Associated Mucocutaneous Disease in Children: Dilemmas in Classification","volume":"31","author":"Prindaville","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/adc.53.1.38","article-title":"Mycoplasma pneumoniae infections in children","volume":"53","author":"Stevens","year":"1978","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jtos.2015.10.002_bib34","article-title":"Mycoplasma pneumoniae-associated mucositis - case report and systematic review of literature","author":"Vujic","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jtos.2015.10.002_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaad.2004.07.044","article-title":"Mycoplasma pneumoniae-induced Stevens-Johnson syndrome without skin lesions: fact or fiction?","volume":"52","author":"Schalock","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00002018-200225130-00006","article-title":"Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience","volume":"25","author":"Forman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtos.2015.10.002_bib37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2500\/108854195778666847","article-title":"Virus induced erythema multiforme and Stevens-Johnson syndrome","volume":"16","author":"Choy","year":"1995","journal-title":"Allergy Proc"},{"key":"10.1016\/j.jtos.2015.10.002_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2500\/108854196778645056","article-title":"Recurrent Stevens-Johnson syndrome secondary to herpes simplex: a follow up on a successful management program","volume":"17","author":"Cheriyan","year":"1996","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jtos.2015.10.002_bib39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1046\/j.1365-2133.1996.d01-1111.x","article-title":"Photo-induced toxic epidermal necrolysis caused by clobazam","volume":"135","author":"Redondo","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0781.2005.00149.x","article-title":"A\u00a0case of toxic epidermal necrolysis with lesions mostly on sun-exposed skin","volume":"21","author":"Mansur","year":"2005","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jtos.2015.10.002_bib41","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/COC.0b013e31825d5835","article-title":"Erythema multiforme, Stevens Johnson Syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review","volume":"37","author":"Vern-Gross","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtos.2015.10.002_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00001813-200309000-00012","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine","volume":"14","author":"Sommers","year":"2003","journal-title":"Anti-cancer Drugs"},{"key":"10.1016\/j.jtos.2015.10.002_bib43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1592\/phco.19.3.223.30917","article-title":"Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies","volume":"19","author":"Micali","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtos.2015.10.002_bib44","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.33588\/rn.3811.2004018","volume":"38","author":"Gomez-Criado","year":"2004","journal-title":"Rev Neurol"},{"key":"10.1016\/j.jtos.2015.10.002_bib45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/B:NEON.0000014538.31561.bc","article-title":"Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider","volume":"66","author":"Aguiar","year":"2004","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jtos.2015.10.002_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000027505","article-title":"Stevens-Johnson syndrome in India - risk factors, ocular manifestations and management","volume":"214","author":"Pushker","year":"2000","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jtos.2015.10.002_bib47","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib48","first-page":"1325","volume":"32","author":"Caumes","year":"2003","journal-title":"Presse Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-200326020-00004","article-title":"Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions","volume":"26","author":"Leone","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtos.2015.10.002_bib50","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1086\/502233","article-title":"Toxic epidermal necrolysis after topical intranasal application of mupirocin","volume":"24","author":"Praz","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jtos.2015.10.002_bib51","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaad.2005.04.076","article-title":"Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops","volume":"53","author":"Florez","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib52","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/ICO.0b013e318172fc15","article-title":"Toxic epidermal necrolysis induced by sulfonamide eyedrops","volume":"27","author":"Fine","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2015.10.002_bib53","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1440-0960.2012.00936.x","article-title":"Toxic epidermal necrolysis caused by over the counter eyedrops","volume":"54","author":"Byrom","year":"2013","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0151-9638(07)89206-4","volume":"134","author":"Schmutz","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jtos.2015.10.002_bib55","first-page":"47","volume":"25","author":"Asensio-Sanchez","year":"2008","journal-title":"An Med Interna"},{"key":"10.1016\/j.jtos.2015.10.002_bib56","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archderm.141.7.907","article-title":"Pseudoephedrine-induced toxic epidermal necrolysis","volume":"141","author":"Nagge","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib57","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1038\/srep04862","article-title":"Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement","volume":"4","author":"Ueta","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtos.2015.10.002_bib58","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1038\/srep05981","article-title":"Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications","volume":"4","author":"Ueta","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtos.2015.10.002_bib59","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1445-5994.2005.00790.x","article-title":"Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"35","author":"Lin","year":"2005","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtos.2015.10.002_bib60","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0738-081X(98)00011-X","article-title":"Drug-induced toxic epidermal necrolysis","volume":"16","author":"Wolkenstein","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib61","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jtos.2015.10.002_bib62","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1756-0500-5-205","article-title":"Oral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome","volume":"5","author":"Kumar","year":"2012","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jtos.2015.10.002_bib63","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1097\/00003246-200211000-00029","article-title":"Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's syndrome) after putative beta-lactam cross-reactivity: Case report and scrutiny of antibiotic imputability","volume":"30","author":"Paquet","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.iac.2004.03.011","article-title":"Sulfonamide hypersensitivity","volume":"24","author":"Slatore","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jtos.2015.10.002_bib65","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajo.2004.02.019","article-title":"Presumed \u201csulfa allergy\u201d in\u00a0patients with intracranial hypertension treated with acetazolamide or\u00a0furosemide: cross-reactivity, myth or reality?","volume":"138","author":"Lee","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2015.10.002_bib66","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib67","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archderm.1987.01660330067010","article-title":"Treatment of toxic epidermal necrolysis. Creteil's experience","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/archderm.1953.01540090096013","article-title":"Nikolsky sign; page from notable contributors to the knowledge of dermatology","volume":"68","author":"Goodman","year":"1953","journal-title":"AMA Arch Derm Syphilol"},{"key":"10.1016\/j.jtos.2015.10.002_bib69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1542-0124(12)70234-3","article-title":"The ophthalmologist's role in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"8","author":"Fu","year":"2010","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2015.10.002_bib70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0738-081X(93)90156-7","article-title":"Drug-induced toxic epidermal necrolysis. II. Current aspects","volume":"11","author":"Roujeau","year":"1993","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib71","article-title":"Complications of Stevens-Johnson syndrome beyond the eye and skin","author":"Saeed","year":"2015","journal-title":"Burns"},{"key":"10.1016\/j.jtos.2015.10.002_bib72","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1346-8138.1998.tb02450.x","article-title":"Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium","volume":"25","author":"Sugimoto","year":"1998","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib73","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70196-0","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Wolkenstein","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jtos.2015.10.002_bib74","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1365-4632.2011.05007.x","article-title":"Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"50","author":"Ang","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib75","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2230.2010.03826.x","article-title":"Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre","volume":"35","author":"Rajaratnam","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib76","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archderm.1984.01650420031010","article-title":"Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator","volume":"120","author":"Westly","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib77","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib78","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/archdermatol.2009.233","article-title":"Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis","volume":"145","author":"Gaultier","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib79","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF02343438","article-title":"Esophageal stricture secondary to drug-induced toxic epidermal necrolysis","volume":"14","author":"Herman","year":"1984","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.jtos.2015.10.002_bib80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1590\/S0004-27492003000100013","volume":"66","author":"Nogueira","year":"2003","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jtos.2015.10.002_bib81","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/BF03262001","article-title":"Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"35","author":"Butt","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtos.2015.10.002_bib82","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11588460-000000000-00000","article-title":"Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"34","author":"Butt","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtos.2015.10.002_bib83","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib84","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib85","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archderm.1995.01690230046008","article-title":"Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome","volume":"131","author":"Cote","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib86","first-page":"243","article-title":"From erythema multiforme to toxic epidermal necrolysis. Same spectrum or different diseases?","volume":"149","author":"Tomasini","year":"2014","journal-title":"G\u00a0Ital Dermatol Venereol"},{"key":"10.1016\/j.jtos.2015.10.002_bib87","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib88","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib89","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"The J Investigative Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib90","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00004630-199711000-00009","article-title":"Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage","volume":"18","author":"Engelhardt","year":"1997","journal-title":"J\u00a0Burn Care Rehab"},{"key":"10.1016\/j.jtos.2015.10.002_bib91","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archderm.141.6.683","article-title":"Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis","volume":"141","author":"Quinn","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib92","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib93","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1684\/ejd.2011.1510","article-title":"Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN)","volume":"21","author":"Watanabe","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.12788\/j.sder.0059","article-title":"Severe cutaneous adverse reactions: impact of immunology, genetics, and pharmacology","volume":"33","author":"Harp","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jtos.2015.10.002_bib95","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/nm1208-1311","article-title":"Saving the skin from durg-induced detachment","volume":"14","author":"Nickoloff","year":"2008","journal-title":"Nature Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib96","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jtos.2015.10.002_bib97","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1212\/WNL.0000000000001034","article-title":"Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions","volume":"83","author":"Chen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jtos.2015.10.002_bib98","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2133\/dmpk.DMPK-11-NT-120","article-title":"Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome\/toxic epidermal necrolysis in Japanese","volume":"27","author":"Maekawa","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jtos.2015.10.002_bib99","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1533-2500.2011.00479.x","article-title":"HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain","volume":"12","author":"Kulkantrakorn","year":"2012","journal-title":"Pain Pract"},{"key":"10.1016\/j.jtos.2015.10.002_bib100","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00228-011-1009-4","article-title":"Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients","volume":"67","author":"Zhang","year":"2011","journal-title":"EurJ Clin Pharmacol"},{"key":"10.1016\/j.jtos.2015.10.002_bib101","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jtos.2015.10.002_bib102","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1744-313X.2011.01011.x","article-title":"A\u00a0study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"38","author":"Cristallo","year":"2011","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.jtos.2015.10.002_bib103","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population","volume":"50","author":"Chang","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib104","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/archdermatol.2010.364","article-title":"HLA-B*1502 allele associated with carbamazepine-induced epidermal necrolysis","volume":"146","author":"Odueyungbo","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2217\/pgs.10.54","article-title":"HLA-B*5901 is strongly associated\u00a0with methazolamide-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Kim","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jtos.2015.10.002_bib106","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B*1511 is a risk factor\u00a0for\u00a0carbamazepine-induced Stevens-Johnson syndrome and toxic\u00a0epidermal necrolysis in Japanese patients","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jtos.2015.10.002_bib107","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jtos.2015.10.002_bib108","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A\u00a0European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jtos.2015.10.002_bib109","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jtos.2015.10.002_bib110","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jtos.2015.10.002_bib111","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000102045","article-title":"Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?","volume":"215","author":"Dainichi","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.jtos.2015.10.002_bib112","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib113","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0161-6420(96)30491-0","article-title":"HLA typing in patients with ocular manifestations of Stevens-Johnson syndrome","volume":"103","author":"Power","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2015.10.002_bib114","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtos.2015.10.002_bib115","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jaci.2014.12.1916","article-title":"IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe mucosal involvement","volume":"135","author":"Ueta","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib116","first-page":"581","volume":"116","author":"Nakaji","year":"2012","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.jtos.2015.10.002_bib117","first-page":"550","article-title":"HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese","volume":"14","author":"Ueta","year":"2008","journal-title":"Mol Vis"},{"key":"10.1016\/j.jtos.2015.10.002_bib118","doi-asserted-by":"crossref","first-page":"e43650","DOI":"10.1371\/journal.pone.0043650","article-title":"HLA-A*0206 with TLR3 polymorphisms exerts more than additive effects in Stevens-Johnson syndrome with severe ocular surface complications","volume":"7","author":"Ueta","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtos.2015.10.002_bib119","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2012.01.069","article-title":"Epistatic interaction between Toll-like receptor 3 (TLR3) and prostaglandin E receptor 3 (PTGER3) genes","volume":"129","author":"Ueta","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib120","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/bjo.2006.113449","article-title":"Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome","volume":"91","author":"Ueta","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2015.10.002_bib121","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.preteyeres.2012.05.003","article-title":"Ocular surface inflammation is regulated by innate immunity","volume":"31","author":"Ueta","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jtos.2015.10.002_bib122","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1167\/iovs.07-1401","article-title":"Association of combined IL-13\/IL-4R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications","volume":"49","author":"Ueta","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2015.10.002_bib123","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.jaci.2007.07.048","article-title":"Association of IL4R polymorphisms with Stevens-Johnson syndrome","volume":"120","author":"Ueta","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib124","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjo.2007.136796","article-title":"Association of Fas Ligand gene polymorphism with Stevens-Johnson syndrome","volume":"92","author":"Ueta","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2015.10.002_bib125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00403-012-1305-6","article-title":"Genetic association of IFN-gamma\u00a0+874T\/A polymorphism in Mexican patients with drug-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"305","author":"Charli-Joseph","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jtos.2015.10.002_bib126","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0733-8635(05)70309-0","article-title":"New advances in severe adverse drug reactions","volume":"19","author":"Revuz","year":"2001","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jtos.2015.10.002_bib127","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMcp043986","article-title":"Clinical practice. Antibiotic allergy","volume":"354","author":"Gruchalla","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib128","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9120(00)00146-6","article-title":"A\u00a0novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes","volume":"33","author":"Neuman","year":"2000","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jtos.2015.10.002_bib129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib130","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archderm.1994.01690050066011","article-title":"Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine","volume":"130","author":"Friedmann","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib131","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib132","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archderm.138.1.29","article-title":"Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples","volume":"138","author":"Correia","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib133","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0091-6749(00)90191-X","article-title":"Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response","volume":"105","author":"Leyva","year":"2000","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib134","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors","volume":"119","author":"Le Cleach","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib136","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"The Journal of investigative dermatology"},{"key":"10.1016\/j.jtos.2015.10.002_bib137","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000372-200010000-00005","article-title":"Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis","volume":"22","author":"Paquet","year":"2000","journal-title":"Am Journal Dermatopathol"},{"key":"10.1016\/j.jtos.2015.10.002_bib138","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2133.1990.tb08240.x","article-title":"Monoclonal antibody MAC 387 recognizes a myelomonocytic antigen shared by epithelial cells in inflammatory skin diseases","volume":"122","author":"Kirkham","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib139","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2133.2000.03595.x","article-title":"Cytological alterations in\u00a0dermal dendrocytes in\u00a0vitro: evidence for transformation to a non-dendritic phenotype","volume":"143","author":"Monteiro","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib140","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000069961","article-title":"Factor-XIIIa-positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome): paradoxical activation in skin and rarefaction in lymph nodes","volume":"206","author":"Paquet","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jtos.2015.10.002_bib141","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib142","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.1997.03890430055008","article-title":"Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration","volume":"133","author":"Inachi","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib143","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1523-1747.2000.00037.x","article-title":"Death receptors in cutaneous biology and disease","volume":"115","author":"Wehrli","year":"2000","journal-title":"The J Invest Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib144","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.cdd.4401185","article-title":"Protein-based therapeutic approaches targeting death receptors","volume":"10","author":"French","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jtos.2015.10.002_bib145","doi-asserted-by":"crossref","first-page":"16183","DOI":"10.1074\/jbc.M212188200","article-title":"Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions","volume":"278","author":"Viard-Leveugle","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtos.2015.10.002_bib146","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/cncr.10277","article-title":"Expression of CD95 (Fas) in sun-exposed human skin and cutaneous carcinomas","volume":"94","author":"Filipowicz","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jtos.2015.10.002_bib147","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jtos.2015.10.002_bib148","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archderm.140.2.242","article-title":"Kinetics and specificity of fas ligand induction in toxic epidermal necrolysis","volume":"140","author":"Chang","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib149","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nm0198-031","article-title":"Downregulation of Fas ligand by shedding","volume":"4","author":"Tanaka","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib150","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4049\/jimmunol.170.2.677","article-title":"Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand","volume":"170","author":"Knox","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib151","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00403-004-0506-z","article-title":"Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens-Johnson syndrome","volume":"296","author":"Gaultier","year":"2004","journal-title":"Archives of dermatological research"},{"key":"10.1016\/j.jtos.2015.10.002_bib152","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtos.2015.10.002_bib153","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib154","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.coi.2007.04.007","article-title":"Apoptosis induced by the lymphocyte effector molecule perforin","volume":"19","author":"Bolitho","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib155","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib156","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib157","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib158","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1600-0560.1999.tb01848.x","article-title":"Epidermal calprotectin in drug-induced toxic epidermal necrolysis","volume":"26","author":"Paquet","year":"1999","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jtos.2015.10.002_bib159","first-page":"145","article-title":"Keratinocyte injury in drug-induced toxic epidermal necrolysis: Simultaneous but distinct topographic expression of CD95R and calprotectin","volume":"10","author":"Paquet","year":"2002","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1523-1747.2000.00816.x","article-title":"Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"114","author":"Lerner","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib161","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of\u00a0causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib162","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstruct Surg"},{"key":"10.1016\/j.jtos.2015.10.002_bib163","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A\u00a0multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J\u00a0Burn Care Rehab"},{"key":"10.1016\/j.jtos.2015.10.002_bib164","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/milmed\/167.8.701","article-title":"A\u00a0case report and a proposed algorithm for the transfer of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis to a burn center","volume":"167","author":"Ellis","year":"2002","journal-title":"Military Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00004630-199601000-00008","article-title":"Experience with toxic epidermal necrolysis treated in a burn center","volume":"17","author":"Yarbrough","year":"1996","journal-title":"J\u00a0Burn Care Rehab"},{"key":"10.1016\/j.jtos.2015.10.002_bib166","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0305-4179(95)00140-9","article-title":"Toxic epidermal necrolysis in a burns centre: a 6-year review","volume":"22","author":"Khoo","year":"1996","journal-title":"Burns"},{"key":"10.1016\/j.jtos.2015.10.002_bib167","first-page":"347","article-title":"Treatment of toxic epidermal necrolysis in a burn center","volume":"93","author":"Yarbrough","year":"1997","journal-title":"J\u00a0S Carolina Med Assoc"},{"key":"10.1016\/j.jtos.2015.10.002_bib168","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.burns.2007.06.008","article-title":"Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients","volume":"34","author":"Boorboor","year":"2008","journal-title":"Burns"},{"key":"10.1016\/j.jtos.2015.10.002_bib169","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A\u00a010-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J\u00a0Burn Care Rehab"},{"key":"10.1016\/j.jtos.2015.10.002_bib170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MD.0b013e3181ca4290","article-title":"Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures","volume":"89","author":"de Prost","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtos.2015.10.002_bib171","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00004630-199920060-00012","article-title":"Management of severe toxic epidermal necrolysis in children","volume":"20","author":"Sheridan","year":"1999","journal-title":"J\u00a0Burn Care Rehab"},{"key":"10.1016\/j.jtos.2015.10.002_bib172","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0022-3476(89)80736-X","article-title":"Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"115","author":"Prendiville","year":"1989","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jtos.2015.10.002_bib173","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1542\/peds.108.5.1162","article-title":"Treatment of extensive toxic epidermal necrolysis in children","volume":"108","author":"Spies","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtos.2015.10.002_bib174","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2133.2012.11074.x","article-title":"The role of prior corticosteroid use\u00a0on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies","volume":"167","author":"Lee","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib175","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archderm.1995.01690180043007","article-title":"Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy","volume":"131","author":"Guibal","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib176","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2340\/0001555571171172","article-title":"Toxic epidermal necrolysis in patients receiving glucocorticosteroids","volume":"71","author":"Rzany","year":"1991","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jtos.2015.10.002_bib177","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1525-1470.2002.00002.x","article-title":"Stevens-Johnson syndrome developing in a girl\u00a0with systemic lupus erythematosus on high-dose corticosteroid therapy","volume":"19","author":"Samimi","year":"2002","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib178","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2133.1976.tb00824.x","article-title":"Erythema multiforme in children. Response to treatment with systemic corticosteroids","volume":"95","author":"Rasmussen","year":"1976","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib179","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00006454-198205000-00005","article-title":"Stevens-Johnson syndrome in children","volume":"1","author":"Ginsburg","year":"1982","journal-title":"Pediatr Infect Dis"},{"key":"10.1016\/j.jtos.2015.10.002_bib180","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s004310050561","article-title":"Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children","volume":"156","author":"Kakourou","year":"1997","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jtos.2015.10.002_bib181","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/adc.83.4.347","article-title":"Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome","volume":"83","author":"Leaute-Labreze","year":"2000","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jtos.2015.10.002_bib182","first-page":"537","volume":"58","author":"Yamane","year":"2009","journal-title":"Arerugi\u00a0= [Allergy]"},{"key":"10.1016\/j.jtos.2015.10.002_bib183","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1046\/j.1365-4362.1997.00100.x","article-title":"Toxic epidermal necrolysis\u2013a retrospective study","volume":"36","author":"Criton","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib184","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jtos.2015.10.002_bib185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jtos.2015.10.002_bib186","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib187","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with stevens-johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib188","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.jtos.2015.10.002_bib189","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen","year":"1995","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.jtos.2015.10.002_bib190","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1365-2230.2001.00910.x","article-title":"Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam","volume":"26","author":"van der Meer","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02834.x","article-title":"Clinical uses of intravenous immunoglobulin","volume":"142","author":"Jolles","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib192","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","article-title":"Manipulating the immune system with immune globulin","volume":"326","author":"Dwyer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib193","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.134.1.80","article-title":"Dermatological uses of high-dose intravenous immunoglobulin","volume":"134","author":"Jolles","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib194","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.0906-6705.2006.00426.x","article-title":"Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis","volume":"15","author":"Paquet","year":"2006","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib195","first-page":"1656","article-title":"Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: potential for therapeutic inhibition","volume":"130","author":"French","year":"2000","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.jtos.2015.10.002_bib196","first-page":"229","article-title":"Immunohistochemical evaluation of toxic epidermal necrolysis treated with human intravenous immunoglobulin","volume":"143","author":"Romanelli","year":"2008","journal-title":"G\u00a0Ital Dermatol Venereol"},{"key":"10.1016\/j.jtos.2015.10.002_bib197","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1742-1241.2003.tb10578.x","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin","volume":"57","author":"Sidwell","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jtos.2015.10.002_bib198","first-page":"392","article-title":"Toxic epidermal necrolysis treated with intravenous immunoglobulin and granulocyte colony-stimulating factor","volume":"41","author":"Kalyoncu","year":"2004","journal-title":"Indian Pediatrics"},{"key":"10.1016\/j.jtos.2015.10.002_bib199","first-page":"266","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin","volume":"155","author":"Simeone","year":"2003","journal-title":"J\u00a0La State Med Soc"},{"key":"10.1016\/j.jtos.2015.10.002_bib200","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1081-1206(10)62065-0","article-title":"Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin","volume":"91","author":"Mayorga","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2015.10.002_bib201","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2005.tb00704.x","article-title":"High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series","volume":"32","author":"Tan","year":"2005","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib203","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2230.2003.01255.x","article-title":"Treatment of toxic epidermal necrolysis in AIDS with intravenous immunoglobulins","volume":"28","author":"Tan","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib204","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1440-0960.1999.00347.x","article-title":"Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin","volume":"40","author":"Phan","year":"1999","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter\u00a0retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib206","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000070957","article-title":"Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study","volume":"207","author":"Prins","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jtos.2015.10.002_bib207","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutairi","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib208","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2003.07.017","article-title":"Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome","volume":"50","author":"Hebert","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib209","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.112.6.1430","article-title":"Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature","volume":"112","author":"Metry","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtos.2015.10.002_bib210","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4067\/S0034-98872009000300009","volume":"137","author":"Molgo","year":"2009","journal-title":"Rev Med Chile"},{"key":"10.1016\/j.jtos.2015.10.002_bib211","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jtos.2015.10.002_bib212","first-page":"1081","article-title":"Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib213","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib214","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-4632.2009.04166.x","article-title":"Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China","volume":"48","author":"Yang","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib215","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib216","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J\u00a0Burn Care Rehab"},{"key":"10.1016\/j.jtos.2015.10.002_bib217","first-page":"2494","article-title":"Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome","volume":"27","author":"Morici","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib218","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J\u00a0Burn Care Rehab"},{"key":"10.1016\/j.jtos.2015.10.002_bib219","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.eye.6701653","article-title":"High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits","volume":"19","author":"Yip","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.jtos.2015.10.002_bib220","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3341\/kjo.2013.27.5.331","article-title":"Effect of age and early intervention with a systemic steroid, intravenous immunoglobulin or amniotic membrane transplantation on the ocular outcomes of patients with Stevens-Johnson syndrome","volume":"27","author":"Kim","year":"2013","journal-title":"Korean J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.jtos.2015.10.002_bib221","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1111\/j.1537-2995.2012.03623.x","article-title":"Plasma and plasma derivatives in therapeutic plasmapheresis","volume":"52","author":"McLeod","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.jtos.2015.10.002_bib222","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib223","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1526-0968.2002.00409.x","article-title":"Plasma exchange in patients with toxic epidermal necrolysis","volume":"6","author":"Bamichas","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.jtos.2015.10.002_bib224","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.1998.tb00094.x","article-title":"A\u00a0study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis","volume":"2","author":"Yamada","year":"1998","journal-title":"Ther Apher"},{"key":"10.1016\/j.jtos.2015.10.002_bib225","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s001340051063","article-title":"Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?","volume":"25","author":"Furubacke","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jtos.2015.10.002_bib226","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/00007611-199909000-00015","article-title":"Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor","volume":"92","author":"Winfred","year":"1999","journal-title":"South Med J"},{"key":"10.1016\/j.jtos.2015.10.002_bib227","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2133.1996.tb01167.x","article-title":"Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis","volume":"135","author":"Goulden","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib228","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2230.1997.tb01044.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor","volume":"22","author":"Jarrett","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib229","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/apc.1997.11.125","article-title":"Management of a patient with advanced AIDS and toxic epidermal necrolysis using human growth hormone and G-CSF","volume":"11","author":"Bae","year":"1997","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jtos.2015.10.002_bib230","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000018112","article-title":"Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?","volume":"198","author":"Paquet","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.jtos.2015.10.002_bib231","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-4362.1989.tb02502.x","article-title":"Drug-induced toxic epidermal necrolysis treated with cyclosporin","volume":"28","author":"Renfro","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib232","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2230.1992.tb02163.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin","volume":"17","author":"Hewitt","year":"1992","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib233","first-page":"473","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J\u00a0Trauma"},{"key":"10.1016\/j.jtos.2015.10.002_bib234","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib235","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib236","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jtos.2015.10.002_bib237","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00007611-199610000-00015","article-title":"Cyclophosphamide in the treatment of toxic epidermal necrolysis","volume":"89","author":"Frangogiannis","year":"1996","journal-title":"South Med J"},{"key":"10.1016\/j.jtos.2015.10.002_bib238","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0190-9622(08)80969-3","article-title":"Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects","volume":"25","author":"Heng","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jtos.2015.10.002_bib239","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of the acute\u00a0ophthalmic manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis disease spectrum","volume":"102","author":"Power","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2015.10.002_bib240","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajo.2008.12.040","article-title":"Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset","volume":"147","author":"Araki","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2015.10.002_bib241","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ophtha.2014.08.013","article-title":"The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome","volume":"122","author":"Kim","year":"2015","journal-title":"Ophthalmology"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154201241500169X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154201241500169X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:42:50Z","timestamp":1748684570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154201241500169X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":241,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S154201241500169X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2015.10.002","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}